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Experience with a single dose of recombinant activated factor
VII for the management of mild-to-moderate bleeds in
haemophilia
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The development of inhibitors to factor VIII or factor IX remains one
of the most challenging complications in the management of haemo-
philia, and greatly compromises the efﬁcacy of replacement therapy.
Despite the option of inhibitor eradication via immune tolerance
therapy, it is estimated that around 30% of patients do not respond to
immune tolerance therapy and will have inhibitors for life [1].
Today, recombinant activated factor VII (rFVIIa; NovoSeven
 ,
Novo Nordisk, Bagsværd, Denmark) is considered the ﬁrst-line
treatment option for controlling bleeding in haemophilia patients with
inhibitors [2]. Standard dosing of rFVIIa facilitates haemostasis by
activating factor X directly on the platelet surface, thereby bypassing
the tenase complex. At higher rFVIIa doses the action is increased
further, resulting in a more stable haemostatic plug with greater
resistance to ﬁbrinolysis [3]. There has, therefore, been debate over the
most effective dosing regimen for rFVIIa in the management of
bleeding episodes in haemophilia patients with inhibitors, and in
particular, interest in the use of a single, higher dose treatment that
may offer the same haemostatic beneﬁt as the traditional standard
dosing regimen of rFVIIa 90 lgk g
)1 given every 2–3 h, but in a more
convenient dosing regimen.
Here, we report our experience on the use of an initial single bolus
dose of rFVIIa (180 lgk g
)1 in children and 150 lgk g
)1 in adults) for
the management of mild-to-moderate bleeding episodes in haemophilia
A patients with inhibitors.
To be eligible for inclusion in the study, patients had to have a
conﬁrmed diagnosis and history of haemophilia with inhibitors and
mild-to-moderate bleeds. Patients gave informed consent (for children
the parent or legal guardian provided this) to receive treatment with
rFVIIa. All enrolled patients were treated within 12 h of the onset of a
bleeding episode. Patients were excluded from the study if they had
severe bleeds, presented for treatment more than 12 h after the onset of
a bleeding episode, or could not be shown to have haemophilia with
inhibitors.
Between March 2006 and January 2008, a total of 35 bleeding
episodes in haemophilia A patients with inhibitors were treated with
rFVIIa, 27 episodes in ﬁve children up to 14 years of age (180 lgk g
)1)
and eight episodes in three adult patients (150 lgk g
)1). The use of a
higher dose of rFVIIa in children reﬂects the known faster clearance of
rFVIIa in paediatric patients.
Bleeding episodes were moderate in 21 (60%) cases and mild in 14
(40%) cases. All doses of rFVIIa were given as a single bolus injection.
If bleeding persisted after initial dosing at either 180 lgk g
)1 or
150 lgk g
)1, a further bolus dose of rFVIIa (90 lgk g
)1) could be
given at 3-hourly intervals until haemostasis was achieved.
Treatment response to rFVIIa dose was classiﬁed as good, partial or
lack of response. A good response was bleeding that stopped following
the initial single dose of 180 or 150 lgk g
)1 rFVIIa; a partial response
wasbleedingthatstoppedfollowingaseconddoseof90 lgk g
)1rFVIIa;
and a lack of response was characterized when bleeding symptoms
persisted after administration of two doses of rFVIIa. Treatment was
considered effective if bleeding resolved with up to two doses of rFVIIa
(good and partial responses). Treatment was considered ineffective if
more than two doses of rFVIIa were needed to stop the bleeding (lack of
responsetorFVIIadoses).Additionalassessmentsmadeduringthestudy
included clinical evaluation of pain, pain relief and tenderness as
reported by the patients, plus measurable changes in haematoma size,
joint mobility and bleeding arrest. These parameters were evaluated at
presentation and 3 h after each rFVIIa infusion.
A single dose of rFVIIa 180 lgk g
)1 stopped mild-to-moderate
bleeding in 59% of bleeding episodes in children. Haemostasis was
achieved after a second dose of 90 lgk g
)1 rFVIIa in a further 37% of
bleeding episodes. One bleeding episode in a child did not stop after
two doses of rFVIIa (4%). In adult patients, a good response was
achieved in 37.5% of cases. Haemostasis was achieved after a second
dose of 90 lgk g
)1 rFVIIa in the remaining 62.5% of bleeding episodes
(Table 1). The response rate was lower in adults, probably because a
higher dose of rFVIIa is necessary for a further increase of thrombin
Table 1. Treatment response to rFVIIa doses in inhibitor patients with
mild-to-moderate bleeds.
rFVIIa dose
(lgk g
)1)
Response to rFVIIa, n (%)
Good Partial
Lack of
response
Children (n = 27) 180 16 (59) 10 (37) 1 (4)
Adults (n = 8) 150 3 (37.5) 5 (62.5)
Total (n = 35) 19 (54) 15 (43) 1 (3)
n, number of bleeding episodes.
Good, haemostasis achieved with initial single dose of rFVIIa; Partial,
haemostasis required an additional 90 lgk g
)1 dose of rFVIIa; Lack of
response, bleeding continued after two doses of rFVIIa.
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arthropathy than the children, which may be another reason for their
lower response. The bleeding response was rated as good in 71% of
patients with mild bleeds and in 42% of those with moderate bleeds.
Overall, in 97% of bleeding episodes the event stopped with only two
doses of rFVIIa (average 1.5 doses). In the 29 joint bleeds, pain and
tenderness disappeared and joint mobility improved after the ﬁrst dose
of rFVIIa in 18 cases (62%). The remaining haemarthroses responded
to a second dose. In all three reported haematomas, the pain
disappeared and haematoma size diminished after two doses of rFVIIa.
It was noted that the response to rFVIIa varied in the three patients
with oral bleeding. In one case, arrest of bleeding was achieved with
the ﬁrst dose of rFVIIa, whereas a second dose of rFVIIa was required
for the second case, and the remaining patient started to re-bleed
within 24 h, despite attaining full haemostasis initially.
No adverse events were reported during the administration of
rFVIIa in this patient cohort.
The recent literature contains a number of reports of the use of a
higher and single dose of rFVIIa to achieve bleeding control in
haemophilia patients with inhibitors. Overall, these studies demon-
strate that a single dose of rFVIIa 270 lgk g
)1 optimizes on-demand
treatment by offering the same level of efﬁcacy and safety as dosing
schedules of rFVIIa 90 lgk g
)1 given every 2–3 h [4,5].
The results of this study support the view that a single high dose of
rFVIIa offers a viable and effective alternative to standard dosing
without altering the safety proﬁle. Although this was a small study
which used single doses of rFVIIa that are lower than those recently
shown to be both effective and well tolerated by adults and children
with haemophilia with inhibitors, it highlights the importance of
optimizing the dose regimen according to local resources and patient
characteristics, such as age, with the possibility of reducing the cost of
the treatment.
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Re: Discordant pair analysis of rFVIIa and pd-aPCC response
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Pharmacology, Bagsvaerd, Denmark
Individuals with haemophilia are routinely encouraged to initiate
treatment for haemarthroses within the ﬁrst few hours after onset of
symptoms to maximize the chances of rapid bleed resolution and
minimize potential damage to joints. However, the two treatment
options for patients with haemophilia with inhibitors are very
different. Recombinant activated coagulation factor VII (rFVIIa;
NovoSeven
 , Novo Nordisk A/S, Bagsvaerd, Denmark) has a short
half-life (2.5 h) and is approved for dosing every 2 h to maximize
control of bleeding through a targeted mechanism of action. Plasma
derived-activated prothrombin concentrates [pd-aPCC, Factor Eight
Inhibitor Bypassing Activity (FEIBA
 ); Baxter AG, Vienna, Austria]
have a slightly longer half-life (4–7 h) administered typically every
12 h [1]. Currently there are only two studies that have compared these
two bypassing agents [2,3].
In the publication of their study comparing rFVIIa and pd-aPCC,
Astermark et al. report that there were signiﬁcant discordant pairs
early after bleed treatment was initiated reﬂecting that patients had
earlier responses to one product as opposed to the other [2]. In the
absence of data showing speciﬁc responses of these patients to both
products, the interpretation by many has been that certain patients
respond better to one or the other product. This idea of differential
response has been highlighted in recent scientiﬁc or CME activities
supported by that trials Sponsor [4].
Astermark et al. comment that the rate of discordant pairs with
regard to efﬁcacy of treatment declines over time, with 43.8% at 2 h
showing different responses to the two bypassing agents, declining to
31.9% at 6 h and 31.1% at 12 h. The authors also note, in agreement
with the ﬁndings of Lusher et al. [5], that earlier initiation of treatment
so as to facilitate effective rapid resolution of bleeding, thereby
potentially minimizing the damage particularly to joints, and reducing
the amount of product required to achieve haemostasis, is particularly
important in the population of patients who may bleed frequently [2].
Recent studies have reinforced this observation with respect to earlier
treatment with rFVIIa and higher efﬁcacy [6].
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